A 70-year-old woman with hypertension and type 2 diabetes presented to the hospital with a cold, pulseless, and pale left leg. On examination, her left leg was found to have mottling and pallor to the level of the proximal left calf. There were absent left femoral, popliteal, or pedal pulses. In contrast, there were palpable pedal pulses on the right side.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcription polymerase chain reaction was positive. Computed tomography angiogram revealed extensive arterial thromboses including nonocclusive thrombus of the infrarenal abdominal aorta near the aortic bifurcation, occlusion of the left common iliac artery, internal iliac artery, and external iliac artery to the level of the iliac ligament with complete occlusion of the popliteal artery below the knee and its branches ([Figure](#fig0001){ref-type="fig"} 1*, left panel*). The patient had no history of venous or arterial clots, no known vasculopathy, minimal underlying atherosclerosis, no personal or family history of hypercoagulable disease, no aortic compression as nidus for thrombus formation, and evaluation for malignancy has been negative to date. An initial hypercoagulable workup ([Table](#tbl0001){ref-type="table"} 1) found a positive lupus anticoagulant by dilute Russell\'s viper venom time and hexagonal phase assays.Figure 1Computed tomography angiogram at initial presentation *(left panel)* and after emergent thrombectomy and thrombolysis *(right panel)*. Consent for publication was obtained from the patient.Figure 1Table 1Laboratory findings on admissionTable 1Laboratory results on admissionReference range[\*](#tb1fn1){ref-type="table-fn"}Platelet count (K/L)217150-450D-dimer (ng/mL)\>4000\<500Prothrombin time (sec)14.611.5-14.5International normalized ratio1.20.9-1.1Activated partial-thromboplastin time (sec)26.623.8-36.6Fibrinogen (mg/dL)320200-450Lactate dehydrogenase (U/L)642135-225Ferritin (ug/L)61713-150High-sensitivity C-reactive protein (mg/L)950-10B2 glycoprotein 1 Ab, IgG (CU)\<6.40-19B2 glycoprotein 1 Ab, IgM (CU)120-19Cardiolipin Ab, IgG (CU)30-19Cardiolipin Ab, IgM (CU)530-19Protein C Resistance4.2\>2.2Dilute Russell\'s viper venom timePositiveNegativeLupus anticoagulant (hexagonal phase)PositiveNegative[^1]

Hypercoagulability and endothelial injury have been described as features of coronavirus disease 2019 (Covid-19). While asymptomatic or symptomatic venous thromboembolism has been frequently observed, arterial thrombosis and acute limb ischemia have less commonly been described.[@bib0001] Lupus anticoagulant has been identified commonly in Covid-19,[@bib0002] and if persistent, is known to be associated with thrombosis in antiphospholipid syndrome. In this case, lupus anticoagulant may have been a false-positive test result in context of acute illness and the receipt of unfractionated heparin. Critical illness and marked inflammatory response in the setting of Covid-19 likely increased propensity for thrombus formation and acute limb ischemia in this patient.

She underwent emergent thrombectomy and thrombolysis and 4-compartment fasciotomy, with limb salvage and revascularization ([Figure](#fig0001){ref-type="fig"} 1*, right panel*). She was initially treated with unfractionated heparin and was bridged to warfarin for maintenance anticoagulation, and discharged to rehabilitation for ongoing recovery. Heightened clinical vigilance is needed for early identification of this potentially serious complication of Covid-19 to facilitate prompt intervention targeting limb salvage,[@bib0003], [@bib0004], [@bib0005], [@bib0006] Further research is needed to determine the role of hypercoagulability in Covid-19, and to identify strategies to prevent and treat venous and arterial thrombosis in this setting.
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[^1]: Reference values are affected by many variables, including the patient population and the laboratory methods used. The ranges used at Brigham and Women\'s Hospital are for adults who are not pregnant and do not have medical conditions that could affect the results. They may therefore not be appropriate for all patients.
